ClinicalTrials.gg
Active, not recruitingNCT07267338Updated Oct 21, 2026

Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

A Phase 2 interventional study of Pembrolizumab & MRG003 in NPC and Locoregionally Advanced Nasopharyngeal Carcinoma, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 21, 2026Now Active, not recruitingStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma — 8 open to participants now, 10 under way, 2 of them phase 3. becotatug vedotin · Nasopharyngeal Carcinoma.

Planned enrollment
6th of 10
35 · median 43
Started
2026
with 7 others
Phase 2
7 of 10
5 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Among the 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma, this one is the 6th largest by planned enrollment, is one of 8 that started in 2026, is one of 7 in phase 2, and was the 3rd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

8 of the 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate efficacy and safety of neoadjuvant of the anti PD1 agent Pembrolizumab combined with MRG003 and adjuvant treatment of Pembrolizumab in patients with Epstein-Barr virus (EBV) - associated locoregionally advanced nasopharyngeal carcinoma.

The expected sample size is 35 patients.

Participants will receive 3 cycles of neoadjuvant pembrolizumab 200mg Q3W plus MRG003 2.3mg/kg Q3W followed by the standard concurrent chemoradiotherapy. Then participants will receive 14 cycles of adjuvant Pembrolizumab 200 mg Q3W after the standard concurrent chemoradiotherapy.

The estimated average length of treatment per patients is 1 year.

Read the detailed description

This is a prospective, single-group, open-label, phase II trial to evaluate the efficacy and safety of 3 cycles of neoadjuvant pembrolizumab and MRG003 followed by concurrent CCRT and 14 cycles of adjuvant pembrolizumab in EBV-associated locoregionally advanced nasopharyngeal carcinoma patients.

The primary objective is to evaluate the Clinical Complete Response (cCR) rate of neoadjuvant pembrolizumab+MRG003 in EBV-associated locoregionally advanced nasopharyngeal carcinoma. The CT/MRI head and neck, chest, upper abdomen for cCR assessment will be performed on week 9±7 days between neoadjuvant therapy and pre CCRT.

Each subject will participate in the trial from the time the subject signs the informed consent form (ICF) through the final protocol-specified contact.

After a screening phase of up to 28 days, each subject will be assigned to receive treatment until disease progression is confirmed, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, or until subjects has received up to 3 cycles pembrolizumab + MRG003, followed Standard concurrent chemoradiotherapy (CCRT), followed up to 14 cycles pembrolizumab (approximately 1 year).

After the end of treatment, each subject will be followed for the occurrence of adverse events.

Subjects who discontinue for reasons other than disease progression will have post-treatment follow-up for disease status until disease progression is confirmed by the site per RECIST 1.1, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed by telephone for overall survival until death, withdrawal of consent or the end of the study.

03

Conditions studied

  • NPC
  • Locoregionally Advanced Nasopharyngeal Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female participants who are at least 18 years of age on the day of signing with confirmed diagnosis of stage III-IVa (Exclude T3N0) nasopharyngeal carcinoma (NPC) will be enrolled in this study.
  2. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  3. Have based on 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  4. sample or newly obtained [core or excisional] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slide. Newly obtained biopsies are preferred to archived tissue.
  5. Have an (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
  6. Epsitein-Barr virus-encoded RNA(EBER) positive.
  7. Epidermal Growth Factor Receptor (EGFR) positive.
  8. Female subjects of should be willing to use 2 methods of or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.
  9. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
  10. Have adequate organ function. Specimens must be collected within 10 days prior to the start of study intervention.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any distant .
  2. Has received prior therapy with EGFR target therapy, or an , anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  3. Has received prior systemic anti-cancer therapy including agents within 4 weeks [could consider shorter interval for kinase inhibitors or other short half-life drugs] prior to [allocation].
  4. Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring . Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.
  5. Has received a or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  6. Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
  7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug.
  8. Known additional that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.
  9. Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.
  10. Has severe (≥Grade 3) to pembrolizumab, MRG003 and/or any of its .
  11. Has active disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)
  12. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  13. Has an active infection requiring systemic therapy.
  14. History of (defined as HBsAg reactive) or known active virus (defined as detectable HCV RNA [qualitative]) infection.

    Note: Testing for Hepatitis B or C is not required unless mandated by local health authority.

  15. Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.

    Note: Hepatitis B and C screening tests are not required unless:

    • Known history of HBV and HCV infection
    • As mandated by local health authority
  16. Has not adequately recovered from major surgery or has ongoing surgical complications.
  17. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  19. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
  20. Has had an allogenic tissue/solid organ transplant.
  21. History of infection. HIV testing is not required unless mandated by local health authority.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Participants will receive 3 cycles of neoadjuvant Pembrolizumab 200 mg IV every 3 weeks (Q3W) combined MRG003 2.0mg/kg IV Q3W followed by standard CCRT and adjuvant treatment of Pembrolizumab 200 mg IV Q3W up to 14 cycles.

    Drug: Pembrolizumab & MRG003

Interventions

  • DrugPembrolizumab & MRG003

    Drug pages: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Becotatug vedotinStudies of Becotatug vedotinBecotatug vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After a screening phase of up to 28 days, each subject will be assigned to receive treatment until disease progression is confirmed, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, or until subjects has received up to 3 cycles pembrolizumab + MRG003, followed Standard concurrent chemoradiotherapy (CCRT), followed up to 14 cycles pembrolizumab.

06

What researchers measure

Primary outcomes

  1. Clinical Complete Response (cCR) rate

    clinical complete response (cCR) rate to neoadjuvant treatment.

    Time frame: cCR assessment will be performed on week 9±7 days between neoadjuvant therapy and pre CCRT

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR, defined as the proportion of participants who have achieved a confirmed complete response (CR), or partial response (PR), which is assessed according to RECIST 1.1 criterial.

    Time frame: To assess the objective response rate of Neoadjuvant therapy of Pembrolizumab in combination with MRG003 at maximum of 9 weeks (up to 3 cycles)

  2. Event-Free Survival (EFS)

    To evaluate neoadjuvant therapy of Pembrolizumab in combination with MRG003 and adjuvant therapy of Pembrolizumab with respect to event-free survival (EFS).

    Time frame: Defined as the time from date of treatment to the date of first documented disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer or death from any cause, up to 36 months

  3. Overall Survival (OS)

    To evaluate neoadjuvant therapy of Pembrolizumab in combination with MRG003 and adjuvant therapy of Pembrolizumab with respect to overall survival (OS).

    Time frame: OS, defined as the time from the date of treatment to the date of death due to any cause, up to 60 months

07

Study locations

1 site
  • Wuhan Xiehe Hospital
    Wuhan, Hubei, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 20 months is below that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Jun 2026 → Feb 2026 and primary completion Dec 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Dec 5, 2025
StartActual
Feb 11, 2026was Jun 2026
Primary completionEst.
Oct 2027was Dec 2027
CompletionEst.
Jun 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 21, 2026
Start date
Jun 2026→Feb 11, 2026 (actual)
Oct 21, 2026
Primary completion
Dec 2027→Oct 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Active, not recruiting
    Start date Jun 2026→Feb 11, 2026 (now actual)
    Primary completion Dec 2027→Oct 2027
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07267338
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Feb 11, 2026
Primary completion
Oct 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Becotatug vedotin

Start the discussion